Aqualung Therapeutics (ALT) is developing multi-pronged strategies to address the development of severe lung inflammation which is essential to the severity and outcomes of acute and chronic lung disorders such as acute lung injury, ventilator-induced lung injury (VILI), idiopathic pulmonary fibrosis, and pulmonary hypertension. Effective FDA-approved drugs are either currently unavailable or extraordinarily modest in their ability to modify disease progression. No drug is currently available that is preventive or curative. Aqualung’s strategies, which include deployment of a human monoclonal antibody which targets a novel inflammatory mediator (nicotinamide phosphoribosyltransferase or NAMPT) will address the unmet need for novel, effective therapies for VILI, IPF, and pulmonary hypertension.
View Top Employees from AQUALUNG THERAPEUTICS CORPORATIONWebsite | http://aqualungtherapeutics.com |
Revenue | $3 million |
Employees | 2 (1 on RocketReach) |
Founded | 2010 |
Address | 1790 E River Rd Suite 205, Tucson, Arizona 85718, US |
Phone | (312) 618-7337 |
Technologies |
JavaScript,
HTML,
PHP
+16 more
(view full list)
|
Industry | Biotechnology, Business Services General, Medical, Business Services, Health Care |
Competitors | Boehringer Ingelheim Venture Fund, Pulmatrix Inc., REGiMMUNE Corporation |
SIC | SIC Code 87 Companies, SIC Code 873 Companies |
NAICS | NAICS Code 54 Companies, NAICS Code 541714 Companies, NAICS Code 5417 Companies, NAICS Code 54171 Companies, NAICS Code 541 Companies |
Looking for a particular AQUALUNG THERAPEUTICS CORPORATION employee's phone or email?
The AQUALUNG THERAPEUTICS CORPORATION annual revenue was $3 million in 2024.
Stan Miele is the President and Co-Founder of AQUALUNG THERAPEUTICS CORPORATION.
1 people are employed at AQUALUNG THERAPEUTICS CORPORATION.
AQUALUNG THERAPEUTICS CORPORATION is based in Tucson, Arizona.
The NAICS codes for AQUALUNG THERAPEUTICS CORPORATION are [54, 541714, 5417, 54171, 541].
The SIC codes for AQUALUNG THERAPEUTICS CORPORATION are [87, 873].